Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Journal of Biomedical Informatics
|
July 8, 2018
From narrative descriptions to MedDRA: automagically encoding adverse drug reactions
Carlo Combi, Margherita Zorzi, Gabriele Pozzani, et al.
IEEE Journal of Biomedical and Health Informatics
|
July 31, 2018
Normalizing Spontaneous Reports Into MedDRA: Some Experiments With MagiCoder
Carlo Combi, Margherita Zorzi, Gabriele Pozzani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 7, 2025
Acquired Bleeding Disorders Associated With Immune Checkpoint Inhibitors: An Update
Marco Tuccori, Daniele Focosi, Elena Arzenton, et al.
Expert Opinion on Drug Safety
|
November 24, 2016
Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system
Lara Magro, Elena Arzenton, Ugo Moretti, et al.
Frontiers in Pharmacology
|
February 4, 2021
Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database
Lara Magro, Elena Arzenton, Roberto Leone, et al.
British Journal of Clinical Pharmacology
|
January 1, 2024
PAttern of drug use in PEdiatrics: An observational study in Italian hOSpitals (the PAPEOS study)
Marta Di Salvo, Greta Santi Laurini, Domenico Motola, et al.
Expert Opinion on Drug Safety
|
April 7, 2018
Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers
Fabio Lugoboni, Antonio Mirijello, Laura Morbioli, et al.
Expert Opinion on Drug Safety
|
September 15, 2019
Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®
Carla Carnovale, Faizan Mazhar, Elena Arzenton, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
March 15, 2024
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Paola Maria Cutroneo, Elena Arzenton, Fabiana Furci, et al.
Drug Safety
|
November 18, 2022
Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database
Chiara Gastaldon, Georgios Schoretsanitis, Elena Arzenton, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Journal of Biomedical Informatics
|
July 8, 2018
From narrative descriptions to MedDRA: automagically encoding adverse drug reactions
Carlo Combi, Margherita Zorzi, Gabriele Pozzani, et al.
IEEE Journal of Biomedical and Health Informatics
|
July 31, 2018
Normalizing Spontaneous Reports Into MedDRA: Some Experiments With MagiCoder
Carlo Combi, Margherita Zorzi, Gabriele Pozzani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 7, 2025
Acquired Bleeding Disorders Associated With Immune Checkpoint Inhibitors: An Update
Marco Tuccori, Daniele Focosi, Elena Arzenton, et al.
Expert Opinion on Drug Safety
|
November 24, 2016
Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system
Lara Magro, Elena Arzenton, Ugo Moretti, et al.
Frontiers in Pharmacology
|
February 4, 2021
Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database
Lara Magro, Elena Arzenton, Roberto Leone, et al.
British Journal of Clinical Pharmacology
|
January 1, 2024
PAttern of drug use in PEdiatrics: An observational study in Italian hOSpitals (the PAPEOS study)
Marta Di Salvo, Greta Santi Laurini, Domenico Motola, et al.
Expert Opinion on Drug Safety
|
April 7, 2018
Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers
Fabio Lugoboni, Antonio Mirijello, Laura Morbioli, et al.
Expert Opinion on Drug Safety
|
September 15, 2019
Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®
Carla Carnovale, Faizan Mazhar, Elena Arzenton, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
March 15, 2024
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Paola Maria Cutroneo, Elena Arzenton, Fabiana Furci, et al.
Drug Safety
|
November 18, 2022
Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database
Chiara Gastaldon, Georgios Schoretsanitis, Elena Arzenton, et al.
Page
of 2